ALDX Aldeyra Therapeutics Inc.: Enterprise Value to EBITDA Ratio

Through its partnership with a pharmaceutical behemoth, Aldeyra Therapeutics (ALDX) protects its market share by leveraging a scalable production model, where low bottling costs following FDA approval ensure a sharp surge in profits. The stock price trend on the GURU.Markets platform, based on the EV/EBITDA metric, stands at 0.00, complementing the profile of a company developing non-hormonal agents to combat toxic aldehydes in the treatment of chronic dry eye.

Aldeyra Therapeutics Inc. - ALDX Company Value to EBITDA (period 11/23/2025 - 11/13/2026)

Metric breakdowns and analytics for aldeyra.com (ALDX)

- current price and projected stock value:

Stock Price Aldeyra Therapeutics, Inc.|ALDX - Average Forecast Price

- company stock capitalization data:

Market Valuation Aldeyra Therapeutics, Inc.|ALDX - Total Enterprise Value

- business book valuation details:

Book Value per Share Aldeyra Therapeutics|ALDX - Total Stockholders' Equity|Market Value to Book Value Ratio aldeyra.com|ALDX - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

ALDX - Company Net Income|Expected Profit Aldeyra Therapeutics|ALDX - Company Value to Net Income|Forward P/E Multiple Aldeyra Therapeutics, Inc.|ALDX - PEG Multiple|Enterprise Value to EBITDA Ratio Aldeyra Therapeutics, Inc.|ALDX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Aldeyra Therapeutics|ALDX - Earnings per share for the last four quarters|Quarterly EPS earnings growth aldeyra.com|ALDX - Earnings per share increase in current year|Earnings growth forecast for next year Aldeyra Therapeutics

- revenue and sales details:

ALDX - Company Total Revenue|Company Projected Revenue Aldeyra Therapeutics, Inc.|ALDX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Aldeyra Therapeutics, Inc.

Summary company analytics:Aldeyra ALDX

Product sample of Aldeyra Therapeutics, Inc.

The EV/EBITDA multiple determines the value of a business relative to its operating profit, accounting for net debt and taxes. The trend in the EV/EBITDA valuation metric reflects the market value of capital in comparison to cash generation efficiency. This calculation allows an investor to assess the payback period of assets regardless of the financing structure. For Aldeyra Therapeutics (ALDX), this metric is critical when evaluating the commercialization of the innovative drug reproxalap within the ophthalmology segment.

Competitor analysis for Aldeyra Therapeutics

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Viridian Corp (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LENZ|EV/EBITDA Multiple Oculis Holding AG (OCS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EyePoint Pharmaceuticals, Inc. EYPT|Kodiak Sciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kala Pharmaceuticals - EV/EBITDA Multiple|IRD (Opus Genetics Inc) - Enterprise Value to Operating Income Before Depreciation|OKYO: EV/EBITDA Multiple|Company Value to EBITDA Adverum Biotechnologies, Inc. (ADVM)|Enterprise Value to EBITDA Ratio OTLK|Company Value to EBITDA Clearside Biomedical Inc CLSD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NovaBay Pharmaceuticals (NBY)|KPRX (kiorapharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALIM (Alimera Sciences, Inc.)|EV/EBITDA Multiple Eyenovia Inc. EYEN|GHSI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OCUP (Ocuphire Pharma Inc)|OPT (Opthea Ltd.) - Enterprise Value to EBITDA Ratio